Skip to main content
RT @DrMiniDey: Freq & severity of adverse events after #SARSCoV2 #vaccine in patients with autoimmune disease vs con

Mrinalini Dey DrMiniDey

4 years 10 months ago
Freq & severity of adverse events after #SARSCoV2 #vaccine in patients with autoimmune disease vs controls Abs#0104 #ACR21 •No incr. risk of AEs in autoimmune disease vs controls •Minimal impact of vaccines on disease activity @RheumNow https://t.co/jGXP5UL4LP https://t.co/980NLWQYeX
RT @drdavidliew: Well done 👏@DrCMcMaster @victor_yang1 on this great work - using machine learning to pick apart GCA

David Liew drdavidliew

4 years 10 months ago
Well done 👏@DrCMcMaster @victor_yang1 on this great work - using machine learning to pick apart GCA from its mimics. Predicting mimics improves prediction, especially in the quagmire of biopsy-negative GCA (also excellent memes in this Twitter thread) #ACR21 ABST1417 @RheumNow https://t.co/cS3fMLwem4
RT @drdavidliew: @RheumNow Janet Zeide @Wharton - if the purpose = persuade:
e.g. persuading an audience, persuading pts

David Liew drdavidliew

4 years 10 months ago
@RheumNow Janet Zeide @Wharton - if the purpose = persuade: e.g. persuading an audience, persuading pts to change - ethos/logos/pathos - remove barriers to action (cost of not changing, incremental change) - state & refute counter-arguments - know & engage your audience #ACR21 @RheumNow https://t.co/JU2WeNYDvz
RT @drdavidliew: So how do we treat this long COVID thing?

Some sensible hints here, but sadly I can't really say that

David Liew drdavidliew

4 years 10 months ago
So how do we treat this long COVID thing? Some sensible hints here, but sadly I can't really say that we've got this under control. I feel helpless with the long COVID patients I've cared for. #ACR21 8M406 @RheumNow @galbamd @CCalabreseDO @philipcrobinson https://t.co/Vaw0QlUx50
RT @drdavidliew: Given the choice, you want me to risk long COVID?
No thanks. #GetVaccinated

#ACR21 8M406 @RheumNow @ga

David Liew drdavidliew

4 years 10 months ago
Given the choice, you want me to risk long COVID? No thanks. #GetVaccinated #ACR21 8M406 @RheumNow @galbamd @CCalabreseDO @philipcrobinson https://t.co/TCao34vWK8
RT @MeralElRamahiMD: This is priceless:
“Learning from our patients is a key highlight of #ACR21.” — Dr. S. Bhana

Meral K. El Ramahi, MD MeralElRamahiMD

4 years 10 months ago
This is priceless: “Learning from our patients is a key highlight of #ACR21.” — Dr. S. Bhana I could not agree more: a patient’s insight is invaluable, irreplaceable, and essential. @RheumNow https://t.co/kS0NWVIpiG
RT @MeralElRamahiMD: Knowledge Bowl at #ACR21

⭐️AMBITION trial data suggested combination of these meds might be mo

Meral K. El Ramahi, MD MeralElRamahiMD

4 years 10 months ago
Knowledge Bowl at #ACR21 ⭐️AMBITION trial data suggested combination of these meds might be more effective than either alone in patients with pulmonary arterial HTN. ➡️Ambrisentan + tadalafil @RheumNow
RT @MeralElRamahiMD: Knowledge Bowl at #ACR21

⭐️This type of vasculitis is most likely to cause proptosis

➡️G

Meral K. El Ramahi, MD MeralElRamahiMD

4 years 10 months ago
Knowledge Bowl at #ACR21 ⭐️This type of vasculitis is most likely to cause proptosis ➡️GPA @RheumNow
RT @MeralElRamahiMD: Knowledge Bowl at #ACR21

⭐️This protean tumefactive disease can rarely present with orbital my

Meral K. El Ramahi, MD MeralElRamahiMD

4 years 10 months ago
Knowledge Bowl at #ACR21 ⭐️This protean tumefactive disease can rarely present with orbital myositis. ➡️IgG4-related Disease @RheumNow
RT @MeralElRamahiMD: Knowledge Bowl at #ACR21

⭐️This is the most common chest imaging finding in a patient with rel

Meral K. El Ramahi, MD MeralElRamahiMD

4 years 10 months ago
Knowledge Bowl at #ACR21 ⭐️This is the most common chest imaging finding in a patient with relapsing chondritis ➡️ Tracheal Stenosis @RheumNow
RT @KDAO2011: Dr. K Costenbader #ACR21 #YearinReview will cover important studies for #ClinicalPractice:
👉add on The

TheDaoIndex KDAO2011

4 years 10 months ago
Dr. K Costenbader #ACR21 #YearinReview will cover important studies for #ClinicalPractice: 👉add on Therapies 👉 the JAK evolution 👉improving clinical care 👉disparities in care @RheumNow https://t.co/dp1oeYMh8n
RT @KDAO2011: 👉Voclosporin for SLE: rapid control of proteinuria (50% reduction over 29 days in UPCR w/o high side ef

TheDaoIndex KDAO2011

4 years 10 months ago
👉Voclosporin for SLE: rapid control of proteinuria (50% reduction over 29 days in UPCR w/o high side effects) @rheumnow #YearInReview #ACR21 Are you all starting to use this drug now? It has helped my patients; pretty well tolerated. https://t.co/zqJRsjnV4n
RT @KDAO2011: Dr. K Costenbader #ACR21 #YearinReview add-ons Rx:
👉Avacopan for AAV: new oral C5a inh allowed for remi

TheDaoIndex KDAO2011

4 years 10 months ago
Dr. K Costenbader #ACR21 #YearinReview add-ons Rx: 👉Avacopan for AAV: new oral C5a inh allowed for remission & prevention of relapse, aggressive pred taper https://t.co/39V3LLOYKZ
RT @KDAO2011: Experts (Drs. M Clowse, Sammaratino) limit mAb TNFi 1 month b/f delivery or extend dosing. But, they do do

TheDaoIndex KDAO2011

4 years 10 months ago
Experts (Drs. M Clowse, Sammaratino) limit mAb TNFi 1 month b/f delivery or extend dosing. But, they do dose again for flares. Risk for infection is low based on the PIANO registry. Postpartum, they restart the meds w/in 1 week (vag delivery), 2 weeks C/S @rheumnow #pregnancy
RT @KDAO2011: Which of the following would you d/c in the 3rd trimester of pregnancy? #ACR21 #Pregnancy @rheumnow

TheDaoIndex KDAO2011

4 years 10 months ago
Which of the following would you d/c in the 3rd trimester of pregnancy? #ACR21 #Pregnancy @rheumnow
×